A rapid assessment of the National Regulatory Systems for medical products in the Southern African Development Community.

Efficacy Institutional frameworks Medical products Medicines National Regulatory Systems, National Regulatory Authorities Quality Regulation SDG Safety South African Development Community UHC

Journal

Journal of pharmaceutical policy and practice
ISSN: 2052-3211
Titre abrégé: J Pharm Policy Pract
Pays: England
ID NLM: 101627192

Informations de publication

Date de publication:
2020
Historique:
received: 22 07 2020
accepted: 18 08 2020
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 9 10 2020
Statut: epublish

Résumé

Access to quality-assured, safe and efficacious medical products is fundamental for Universal Health Coverage and attaining Sustainable Development Goal 3: Ensure Healthy Lives and Well-being for All. To guarantee this right, there is a need for robust and efficiently performing national regulatory systems for the regulation of medical products. Well-functioning regulatory systems apply globally accepted standards which ensure that the level of control is proportionate to the level of public health risk. The study aimed at analysing the regulatory systems for medical products in the 16 Member States of the Southern African Development Community (SADC). It provides an overview of the national regulatory systems for medical products in the region in 2017 and outlines the institutional frameworks, which enable the implementation of regulatory functions. A survey was conducted in March-December 2017 in English, French and Portuguese. National Regulatory Authorities for medical products (NMRAs) of the 16 Member States within SADC responded to the questions asked and sent in their answers. The survey was constructed around five themes instrumental for implementation of the Universal Health Coverage actions framework. Three of the themes are discussed in this article. The outcome of the survey demonstrates that within SADC, NMRAs vary in terms of organisational set-up and modalities of medical product regulation. The majority are within the Ministries of Health, and a few are either semi-autonomous or autonomous. Legal frameworks for medical products are in place for some of the SADC NMRAs, although they vary in the scope of products subject to regulation. Traditional medicines, biologicals and medical devices are regulated, however not uniformly across the region. Despite major progress over the years, the survey demonstrates variable levels of governance and regulatory framework among NMRAs in SADC. The survey supports the need for shifting from the broad strengthening of the regulatory systems which exist and are underpinned by the mandates, to more product-type focused approaches. This shift will ensure that medical products are quality-assured, safe and effective for a performant Health Systems attainment of the Universal Health Coverage and Sustainable Development Goals.

Sections du résumé

BACKGROUND BACKGROUND
Access to quality-assured, safe and efficacious medical products is fundamental for Universal Health Coverage and attaining Sustainable Development Goal 3: Ensure Healthy Lives and Well-being for All. To guarantee this right, there is a need for robust and efficiently performing national regulatory systems for the regulation of medical products. Well-functioning regulatory systems apply globally accepted standards which ensure that the level of control is proportionate to the level of public health risk.
OBJECTIVE OF THE STUDY OBJECTIVE
The study aimed at analysing the regulatory systems for medical products in the 16 Member States of the Southern African Development Community (SADC). It provides an overview of the national regulatory systems for medical products in the region in 2017 and outlines the institutional frameworks, which enable the implementation of regulatory functions.
METHODOLOGY METHODS
A survey was conducted in March-December 2017 in English, French and Portuguese. National Regulatory Authorities for medical products (NMRAs) of the 16 Member States within SADC responded to the questions asked and sent in their answers. The survey was constructed around five themes instrumental for implementation of the Universal Health Coverage actions framework. Three of the themes are discussed in this article.
RESULTS RESULTS
The outcome of the survey demonstrates that within SADC, NMRAs vary in terms of organisational set-up and modalities of medical product regulation. The majority are within the Ministries of Health, and a few are either semi-autonomous or autonomous. Legal frameworks for medical products are in place for some of the SADC NMRAs, although they vary in the scope of products subject to regulation. Traditional medicines, biologicals and medical devices are regulated, however not uniformly across the region.
CONCLUSION CONCLUSIONS
Despite major progress over the years, the survey demonstrates variable levels of governance and regulatory framework among NMRAs in SADC. The survey supports the need for shifting from the broad strengthening of the regulatory systems which exist and are underpinned by the mandates, to more product-type focused approaches. This shift will ensure that medical products are quality-assured, safe and effective for a performant Health Systems attainment of the Universal Health Coverage and Sustainable Development Goals.

Identifiants

pubmed: 33029353
doi: 10.1186/s40545-020-00255-x
pii: 255
pmc: PMC7534171
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

64

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S135-40
pubmed: 26409274
Pharmaceut Med. 2017;31(6):383-397
pubmed: 29200865
Global Health. 2018 Nov 1;14(1):102
pubmed: 30382856
Front Med (Lausanne). 2020 Aug 19;7:457
pubmed: 32974367

Auteurs

S Dube-Mwedzi (S)

SADC Medicines Regulatory Harmonization Project, Harare, Zimbabwe.

S Kniazkov (S)

WHO Regional Office for Africa, Health Technologies and Innovation Unit, Brazzaville, Republic of Congo.

J B Nikiema (JB)

WHO Regional Office for Africa, Health Technologies and Innovation Unit, Brazzaville, Republic of Congo.

O M J Kasilo (OMJ)

WHO Regional Office for Africa, Health Technologies and Innovation Unit, Brazzaville, Republic of Congo.

A Fortin (A)

WHO Regional Office for Africa, Health Technologies and Innovation Unit, Brazzaville, Republic of Congo.

P Tumusiime (P)

WHO Regional Office for Africa, Health Technologies and Innovation Unit, Brazzaville, Republic of Congo.

G N Mahlangu (GN)

Medicines Control Authority of Zimbabwe, Harare, Zimbabwe.

M Ndomondo-Sigonda (M)

African Union Development Agency, New Partnership for Africa's Development, Pretoria, South Africa.

Classifications MeSH